文献速递流行病学与生物统计临床试验与 GCP

低剂量阿司匹林预防子痫前期及相关发病和死亡:美国预防服务工作组更新证据报告与系统综述

Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2021-01-01

阿司匹林剂量范围为50-150 mg/d,与子痫前期风险降低(RR 0.85,95%CI 0.75-0.95)及围产期死亡、早产和宫内生长受限风险降低相关,未发现明显出血或其他危害。

要点

  • 高危孕妇每日低剂量阿司匹林(50-150 mg/d)可降低子痫前期风险(RR 0.85)。
  • 阿司匹林还与围产期死亡、早产和宫内生长受限风险降低相关。
  • 未发现阿司匹林与产后出血或其他出血相关危害的显著关联。

核心结论

  • 孕期每日低剂量阿司匹林与子痫前期高危个体严重围产期结局风险降低相关,且无明确危害。

研究设计与样本

  • 检索MEDLINE、PubMed、EMBASE和Cochrane Central Register of Controlled Trials,文献时限2013年1月至2020年5月15日,持续监测至2021年1月22日。
  • 纳入良好和一般质量的随机对照试验,评估孕期低剂量阿司匹林预防子痫前期的效果及一般人群中的潜在危害。

关键数值与推荐

  • 高危人群试验中子痫前期发生率范围为4%至30%。
  • 阿司匹林剂量范围为50 mg/d至150 mg/d。
  • 较大试验(n>300)中阿司匹林相关子痫前期绝对风险降低范围为-1%至-6%,较小试验中更大。
  • 3项最大试验中围产期死亡绝对风险降低范围为0.5%至1.1%。

临床怎么用

  • 对于子痫前期高危个体,可考虑每日使用低剂量阿司匹林(50-150 mg/d)以降低子痫前期及相关不良围产期结局风险。
  • 决策时应结合个体风险因素评估,并权衡潜在获益与危害。

局限性

  • 多数试验纳入以白人为主的人群,基于多种风险因素选择,可能限制普遍性。
  • 阿司匹林剂量范围较宽,最佳剂量尚未明确。
  • 部分结局存在异质性(如早产I²=49%,宫内生长受限I²=41%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Preeclampsia is a hypertensive disorder of pregnancy that poses serious maternal and infant health risks. Previous systematic reviews have established benefits of low-dose aspirin taken during pregnancy to prevent preeclampsia and its sequelae. OBJECTIVE: To update evidence for the US Preventive Services Task Force (USPSTF) on effectiveness of aspirin use in preventing preeclampsia in individuals at increased risk based on clinical risk factors or measurements associated with higher disease incidence than in the general population. DATA SOURCES: Studies from previous USPSTF review (2014), literature published January 2013 through May 15, 2020, in MEDLINE, PubMed (for publisher-supplied records only), EMBASE, and Cochrane Central Register of Controlled Trials. Ongoing surveillance through January 22, 2021. STUDY SELECTION: Good- and fair-quality randomized clinical trials (RCTs) of low-dose aspirin use during pregnancy to prevent preeclampsia among individuals at increased risk; studies conducted in general populations to evaluate potential harms. DATA EXTRACTION AND SYNTHESIS: Dual article screening and risk-of-bias assessment. Study data abstracted into prespecified forms, checked for accuracy. Random-effects meta-analysis. MAIN OUTCOMES AND MEASURES: Diagnosis of preeclampsia; adverse pregnancy health outcomes and complications including eclampsia, perinatal mortality, preterm birth, small for gestational age, and potential bleeding harms or infant/child harms from aspirin exposure. RESULTS: A total of 23 randomized clinical trials (RCTs) (N = 26 952) were included; 18 were conducted among participants at increased preeclampsia risk. Aspirin dosages ranged from 50 mg/d to 150 mg/d. Most trials enrolled majority White populations selected based on a range of risk factors. The incidence of preeclampsia among the trials of participants at increased risk ranged from 4% to 30%. Aspirin use was significantly associated with lower risk of preeclampsia (pooled relative risk [RR], 0.85 [95% CI, 0.75-0.95]; 16 RCTs [n = 14 093]; I2 = 0%), perinatal mortality (pooled RR, 0.79 [95% CI, 0.66-0.96]; 11 RCTs [n = 13 860]; I2 = 0%), preterm birth (pooled RR, 0.80 [95% CI, 0.67-0.95]; 13 RCTs [n = 13 619]; I2 = 49%), and intrauterine growth restriction (pooled RR, 0.82 [95% CI, 0.68-0.99]; 16 RCTs [n = 14 385]; I2 = 41%). There were no significant associations of aspirin use with risk of postpartum hemorrhage (pooled RR, 1.03 [95% CI, 0.94-1.12]; 9 RCTs [n = 23 133]; I2 = 0%) and other bleeding-related harms, or with rare perinatal or longer-term harms. Absolute risk reductions for preeclampsia associated with aspirin use ranged from -1% to -6% across larger trials (n >300) and were greater in smaller trials. For perinatal mortality, absolute risk reductions ranged from 0.5% to 1.1% in the 3 largest trials. CONCLUSIONS AND RELEVANCE: Daily low-dose aspirin during pregnancy was associated with lower risks of serious perinatal outcomes for individuals at increased risk for preeclampsia, without evident harms.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Henderson JT, Vesco KK, Senger CA, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021. PMID: 34581730. doi:10.1001/jama.2021.8551

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。